# The Silent Pandemic: Antifungal Resistance and the Future of Invasive Fungal Disease Management

## TL;DR

This paper reviews the growing threat of antifungal resistance and offers insights into managing invasive fungal diseases through improved diagnostics and therapies.

## Contribution

The paper provides a comprehensive review of antifungal resistance mechanisms and actionable strategies for clinical management.

## Key findings

- Emerging pathogens like Candida auris and Aspergillus fumigatus are driving antifungal resistance.
- Rapid molecular diagnostics and next-generation sequencing are critical for timely treatment.
- New antifungal agents and stewardship programs are essential to combat resistance.

## Abstract

Invasive fungal diseases (IFDs) represent an escalating global health threat, compounded by the rapid emergence of antifungal resistance (AFR). This review synthesizes the contemporary landscape of AFR from clinical and microbiological perspectives, providing actionable insights for clinical practitioners. We examine the epidemiology of critical pathogens, including Candidozyma auris, clonal Candida parapsilosis, azole-resistant Aspergillus fumigatus, and dissect the underlying molecular mechanisms, from genetic mutations in ERG11 and cyp51A to novel emerging epigenetic and adaptive strategies. We critically appraise the diagnostic gap between phenotypic testing and clinical urgency, highlighting the role of rapid molecular assays and next-generation sequencing. Finally, we evaluate evidence-based therapeutic strategies, including the integration of novel agents such as rezafungin, ibrexafungerp, olorofim, and fosmanogepix), while emphasizing the imperative of antifungal stewardship, infection prevention and control in mitigating resistance, and “One-Health” interventions.